Correction: 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, Jose Baselga, Henry C. Manning, Umar Mahmood, Gary A. Ulaner

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

In the original version of this article (1), the stated disclosure of the author Carlos L. Arteaga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Original languageEnglish (US)
Pages (from-to)1435
Number of pages1
JournalClinical Cancer Research
Volume25
Issue number4
DOIs
StatePublished - Feb 15 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: 18 F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: Using an imaging biomarker to guide drug dosage in subsequent trials(Clin Cancer Res. (2017) 3:12 (3053-3060) DOI: 10.1158/1078-0432.CCR-16-219)'. Together they form a unique fingerprint.

Cite this